TotalMarketCap

Biogen

BIIBNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$32.274 B

$218.43 -1.68%

Close of 9 Oct 2026

As of 9 Oct 2026, Biogen (BIIB) has a market capitalization of $32.3B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$9.89B

#415 by revenue

Earnings

$1.29B

#322 by earnings

Shares outstanding

147,753,998

Latest filing cover page

P/E ratio

25.0

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →
  1. #4Argenx SeARGX$50.8B
  2. #5Revolution MedicinesRVMD$40.3B
  3. #6BiogenBIIB$32.3B
  4. #7BioNTech SEBNTX$23.1B
  5. #8ExelixisEXEL$14.6B

What if Biogen were worth as much as…

Open the what-if tool →

Gold $29.1T

$196,690.82

Per share 900× higher

Bitcoin $1.66T

$11,238.82

Per share 51.5× higher

Nvidia $5.55T

$37,593.35

Per share 172× higher

Or at a round number

$50.0B$100.0B$200.0B$500.0B

Where these numbers come from

Share counts and financials for Biogen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 10 Oct 2026. Read the methodology.